KR900016459A - 사람의 선암(adenocarcinoma)항원에 대한 재조합 및 키메릭 항체 - Google Patents
사람의 선암(adenocarcinoma)항원에 대한 재조합 및 키메릭 항체 Download PDFInfo
- Publication number
- KR900016459A KR900016459A KR1019890005191A KR890005191A KR900016459A KR 900016459 A KR900016459 A KR 900016459A KR 1019890005191 A KR1019890005191 A KR 1019890005191A KR 890005191 A KR890005191 A KR 890005191A KR 900016459 A KR900016459 A KR 900016459A
- Authority
- KR
- South Korea
- Prior art keywords
- dna
- sequence
- plasmid
- amino acid
- recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 플라스미드 pL32의 작제도이다. 도면은 이의 설명을 위하여 정확히 인정한 비율로 도시되지는 않았다,
제2도는 플라스미드 pNM789의 제한부위 및 작용지도이다,
제3도는 플라스미드 120의 작제도이다.
Claims (41)
- 필수적으로 하기의 서열로 구성된 아미노산 잔기서열을 갖는 항체 경쇄(light chain)의 암호화 DNA를 함유함을 특징으로 하는 제조합 DNA화합물.
- 제1항에 있어서, 암호화 분쇄가 하기의 서열을 함유하는 제조합 DNA화합물.
- 제1항 또는2항에 있어서, DNA암호와 서열이 추가로 진핵세포성 리더(leader)펩타이드의 암호와 DNA서열을 함유하는 재조합 DNA화합물.
- 제3항에 있어서, 리더 펨타이드의 암호와 DNA 서열이 하기의 서열을 함유하는 재조합 DNA화합물 ATG GAT TTT CAA GTG CAG ATT TTT AGC TTC CTG CTA ATC AGT GCT TCA GTC ATA ATG TCC AGA CGA.
- 제1항 내지 4항중 어느 한 항에 있어서, 플라스미스 pGKC2310 (NRRL B-18356)인 재조합 DNA화합물.
- 필수적로 하기의 서열로 구성된 아미노산 잔기서열을 가진 항체 종쇄(heavy chan)의 암호와 DNA를 함유함을 특징으로 하는 재조합 DNA 화합물.
- 제5항에 있어서, 암호와 분쇄가 하기의 서열을 함유하는 재조합 DNA화합물.
- 제6항 또는 7항에 있어서, DNA 암호와 서열이 추가로 진핵세포성 리더 펩타이드의 암호와DNA서열을 함유하는 제조합 DNA화합물.
- 제8항에 있어서, 리더 펩타이드의 암호와 DNA서열이 하기의 서열을 함유하는 제조합 DNA화합물 ATG GAT TGG CTG TGG AAC TTG CTA TTC CTG ATG GCA GCT GCC CAA AGT GCC CAA GCA.
- 제6항 내지 9항중 어느 한 항에 있어서, 플라스미드 pG2A52 (NRRL B-18357)인 제조합 DNA화합물.
- 제2항에 따른 DNA서열의 돌연변이되어 생성되지만, KSA에 결합할 수 있는 능력을 유지하는 분자를 발현 생성하는 제조합 DNA서열.
- 제7항에 따른 DNA서열이 돌연변이 되어 생성되지만, KSA에 결합할 수 있는 능력을 유지 하는 분자를 발현 생성하는 재조합 DNA서열.
- 필수적으로 하기의 서열로 구성된 아미노산 서열을 갖는 제1포유류종으로부터 유도된 항원-특이적 가변영역, 및 상이한 제2포유류종으로부터 유도된 불변영역을 함유하는 키메릭(chimeric)항체 경쇄의 암호와 DNA를 함유함을 특징으로 하는 재조합 DNA화합물.
- 제13항에 있어서, 암호화 본쇄가 하기의 서열을 함유하는 재조합 DNA화합물.
- 제1DNA서열이 쥐의 하이브리도마로부터 유도되고 제2DNA서열이 사람 공급원으로부터 유도되는 제14항의 DNA서열을 함유함을 특징으로 하는 제조합 DNA벡터.
- 15항에 있어서, 플라스미드 CHKC2-18 (NRRL B-18359)인 재조합 DNA 벡터.
- 제15항에 있어서, DNA의 발현을 유도하도록 위치한 프로모터 및 해독 활성화 서열을 추가로 함유하는 재조합 DNA 벡터.
- 제17항에 있어서, 실시예 21에 기술된 플라스미드 PL-HD인 재조합 DNA발현벡터.
- 필수적으로 하기의 서열로 구성 된 아미노산 서열을 갖는 제1포유류종으로부터 유도된 항원-특이적 가변영역, 및 상이한 제2포유류종으로부터 유도된 불변영역을 함유하는 키메릭 항체 경쇄를 암호화하는 DNA를 함유함을 특징으로 하는 재조합 DNA화합물.
- 제19항에 있어서, 암호와 본쇄가 하기의 서열을 함유하는 재조합 DNA화합물.
- 제1 DNA서열이 쥐의 하이브리도마로부터 유도되고 제2DNA서열이 사람공급원으로부터 유도되는 제20항의 DNA서열을 함유함을 특징으로 하는 제조합 DNA벡터.
- 제21항에 있어서, 플라스미드 CHKC2-6 (NRRLB-l8358)인 재조합 DNA벡터.
- 필수적으로 하기의 서열로 구성된 아미노산 서열을 갖는 제1포유류종으로부터 유도된 항원 특이적 가변영역, 및 상이한 제2포유류종으로루터 유도된 불변영역을 함유하는 키메릭 항체중쇄의 암호와 DNA를 함유함을 특징으로 하는 제조합 DNA화합물.
- 제23항에 있어서, 암호와 본쇄가 하기의 서열을 함유하는 재조함 DNA화합물.
- 제1 DNA서열이 쥐의 하이브리도마로부터 유도되고 제2DNA서열이 사람 공급원으로부터 유도되는 제23항의 DNA 서열을 함유함을 특징으로 하는 재조합 DNA벡터.
- 제25항에 있어서, 플라스미드 CH2A5 (NRRLB-18360), 플라스미드CH2A5IG2 (NRRLB-18361), 플라스미드 CH2A5IG3 (NRRLB-18362) 또는 플라스미드 CH2A5IG4 (NRRL B-18363)인 재조합 DNA벡터.
- 제25항에 있어서, DNA발현을 유도하도록 위차한 프로모터 해독 활성화 서열을 추가로 함유하는 제조합 DNA벡터.
- 제27항에 있어서, 실시예 23에 기술된 플라스미드 PH-HD, 실시예 24에 기술된 플라스미드 pH2-HD, 실시예 25에 기술된 플라스미드 pH3-HD 또는 실시예 25에 기술된 pH4-HD인 제조합 DNA 발현벡터.
- (1) 제조합 비-임파성 숙주세포를(a)상기의 비-임파성 숙주세포중에서 작용하는 프로모터 및 해독 활성화 서열 및 (b) 제조합 또는 키메릭 항체 쇄(들)을 암호화하고 상기의 프로모터 및 활성화 서열로부터 발현되도록 위치한 DNA서열을 함유하는 제조합 DNA발현벡터(들)로 형질전환시키고, (2) 단계(1)에서 형질전환된 숙주세포를 재조합 또는 키메릭 면역글로불린 쇄의 발현에 적합한 조건하에서 배양시킴을 특징으로 하여, 제조합 및 키메릭 항체 쇄를 제조합 비-암파성 숙주세포중에서 발현시키는 방법.
- 제29항에 있어서, 제조함 숙주세포가 293 세포 또는 AV12 세포로 구성된 그룹중에서 선택되는 방법.
- 제30항에 있어서, 단계(2)의 재조합 숙주세포가 AV12 세포인 방법.
- 제31항에 있어서, 제조합 DNA 발현벡터가 플라스미드 pL-HD, 플라스미드, pHI-HD, 플라스미드 pH2-HD, 플라스미드 pH3-HD 또는 플라스미드 pH4-HD인 방법.
- 필수적으로 하기의 서열로 구성된 아미노산 서열을 갖는 경쇄를 함유함을 특징으로 하는 재조합적으로 생성된 모노클로날 항체.
- 필순직으로 하기의 서열로 구성된 아미노산 서열로 갖는 중쇄를 함유함을 특징으로 하는 재조합적으로 생성된 모노클로날 항체.
- 필수적으로 하기의 서열(A)로 구성된 아미노산 서열을 갖는 경쇄 및 필수적으로 하기의 서 열(B)로 구성된 아미노산 서열을 갖는 중쇄를 함유함을 특징으로 하는 재조합적으로 생성된 모노클로날 항체.
- 필수적으로 하기의 서열로 구성된 아미노산 서열을 갖는 모노클로날 항체 경쇄 시그날 펩타이드, Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser Val Ile Met Ser Arg Gly.
- 필수적으로 하기의 서열로 구성된 아미노산 서열을 갖는 모노클로날 항체 중쇄 시그날 펩타이드, Met Asp TrP Leu Trp Asn Leu Leu Phe Leu Met Ala Ala Ala Gln Ser Ala Gln Ala.
- 필수적으로 하기의 서열로 구성 된 아미노산 서열을 갖는 제1포유류종으로부터 유도된 항원-특이적 가변영역, 및 상이한 제2포유류종으로부터 유도된 불변영역을 함유함을 특징으로 하는 키메릭 모노클로날 항체.
- 필수적으로 하기의 서열로 구성된 아미노산 서열을 갖는 제1포유류종으로부터 유도된 항원-특이적 가변경해 영역 및 상이한 제2포유류종으로부터 유도된 불변영역을 함유함을 특징으로 하는 키메릭 모노클로날 항체.
- 필수적으로 하기의 서열로 구성된 아미노산 서열을 갖는 제1포유류종으로뚜터 유도된 항원-특이적 가변중쇄 영역 및 상이한 제2포유류종으로뚜터 유도된 불변영역을 함유함을 특징으로 하는 키메릭 모노클로날 항체.
- 경쇄 가변영역이 필수적으로 하기의 서열(I)로 구성된 아미노산 서열을 갖고 중쇄 가변영역이 필수적으로 하기의 서열(Ⅱ)로 구성된 아미노산 서열을 갖는 제1포유류종으로부터 유도된 항원-특이적 가변영역, 및 상이한 제2포유류종으로부터 유도된 불변영역을 함유함을 특징으로 하는 키메릭 모노클로날 항체.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/184,522 US4975369A (en) | 1988-04-21 | 1988-04-21 | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
US07/184,522 | 1988-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR900016459A true KR900016459A (ko) | 1990-11-13 |
Family
ID=22677247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019890005191A KR900016459A (ko) | 1988-04-21 | 1989-04-20 | 사람의 선암(adenocarcinoma)항원에 대한 재조합 및 키메릭 항체 |
Country Status (14)
Country | Link |
---|---|
US (1) | US4975369A (ko) |
EP (1) | EP0338767A3 (ko) |
JP (1) | JPH02211877A (ko) |
KR (1) | KR900016459A (ko) |
CN (1) | CN1037174A (ko) |
AU (1) | AU621600B2 (ko) |
DK (1) | DK187889A (ko) |
HU (1) | HUT50870A (ko) |
IL (1) | IL90016A0 (ko) |
NZ (1) | NZ228801A (ko) |
PH (1) | PH26945A (ko) |
PT (1) | PT90312A (ko) |
RU (1) | RU1780541C (ko) |
ZA (1) | ZA892840B (ko) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU643189B2 (en) | 1988-09-06 | 1993-11-11 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
IL89490A0 (en) * | 1988-11-17 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against metal chelates |
CA2044578A1 (en) * | 1989-11-07 | 1991-05-08 | Teruo Kaneda | Mouse antibody v region gene fragments and method of chimeric antibody preparation using said gene fragments |
GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
US5272078A (en) * | 1991-01-29 | 1993-12-21 | Brigham And Women's Hospital | CDNA encoding the type I iodothyronine 5'deiodinase |
WO1992013077A1 (en) * | 1991-01-29 | 1992-08-06 | Brigham And Women's Hospital | A cDNA ENCODING THE TYPE I IODOTHYRONINE 5' DEIODINASE |
US20050196400A1 (en) * | 1991-05-06 | 2005-09-08 | Xoma Technology Ltd. | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
US5756096A (en) * | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5877289A (en) * | 1992-03-05 | 1999-03-02 | The Scripps Research Institute | Tissue factor compositions and ligands for the specific coagulation of vasculature |
US6093399A (en) * | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
US6036955A (en) * | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
US6004555A (en) * | 1992-03-05 | 1999-12-21 | Board Of Regents, The University Of Texas System | Methods for the specific coagulation of vasculature |
US6749853B1 (en) | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
FR2724320B1 (fr) * | 1994-09-13 | 1996-12-20 | Transgene Sa | Nouvel implant pour le traitement des maladies acquises |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
EP1378525A3 (en) * | 1996-06-07 | 2004-01-14 | Neorx Corporation | Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods |
US5916771A (en) * | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6420140B1 (en) * | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
US6348581B1 (en) | 1996-10-31 | 2002-02-19 | The Dow Chemical Company | High affinity humanized anti-TAG-72 monoclonalantibodies |
AU737406B2 (en) | 1997-02-07 | 2001-08-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Activity dependent neurotrophic factor III (ADNF III) |
US6893636B2 (en) | 1997-02-20 | 2005-05-17 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US7033589B1 (en) | 1997-02-20 | 2006-04-25 | Biogen Idec Ma Inc. | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US7147854B2 (en) * | 1997-06-23 | 2006-12-12 | Yes Biotech Laboratories Ltd. | Topical treatment of psoriasis using neutralizing antibodies to interleukin-8 |
ATE267215T1 (de) | 1997-12-08 | 2004-06-15 | Lexigen Pharm Corp | Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
RU2244547C2 (ru) | 1998-05-19 | 2005-01-20 | Рисерч Дивелопмент Фаундейшн | Тритерпеновые композиции и способы их применения |
US6350452B1 (en) | 1998-09-24 | 2002-02-26 | Promega Corporation | Apoptosis marker antibodies and methods of use |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
US7144991B2 (en) | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
US20030143233A1 (en) * | 1999-06-07 | 2003-07-31 | Neorx Corporation | Streptavidin expressed gene fusions and methods of use thereof |
US20030103948A1 (en) * | 1999-06-07 | 2003-06-05 | Neorx Corporation | Streptavidin expressed gene fusions and methods of use thereof |
EP1731531B1 (en) | 1999-08-09 | 2012-05-30 | Merck Patent GmbH | Multiple cytokine-antibody complexes |
EP1228214A2 (en) | 1999-11-12 | 2002-08-07 | MERCK PATENT GmbH | Erythropoietin forms with improved properties |
ATE336514T1 (de) | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
EP1299542A2 (en) * | 2000-06-06 | 2003-04-09 | Idec Pharmaceuticals Corporation | Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
PT1294401E (pt) | 2000-06-29 | 2007-11-09 | Merck Patent Gmbh | Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas |
US20060148732A1 (en) * | 2000-11-17 | 2006-07-06 | Gutterman Jordan U | Inhibition of NF-kappaB by triterpene compositions |
KR20090010127A (ko) | 2001-03-07 | 2009-01-28 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술 |
WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
DK1383785T3 (da) * | 2001-05-03 | 2011-05-23 | Merck Patent Gmbh | Rekombinant tumorspecifikt antistof og anvendelse deraf |
DE60238435D1 (de) * | 2001-10-26 | 2011-01-05 | Scripps Research Inst | Gezielte thrombose durch gewebefaktor polypeptiden |
ATE542137T1 (de) | 2001-12-04 | 2012-02-15 | Merck Patent Gmbh | Immunocytokine mit modulierter selektivität |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
KR20120068769A (ko) | 2002-07-15 | 2012-06-27 | 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 | 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도 |
CA2492883C (en) | 2002-08-01 | 2012-10-02 | James D. Marks | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
US20040053363A1 (en) * | 2002-09-18 | 2004-03-18 | Thomas Ryll | Method for production of a multimeric protein by cell fusion |
US20040053359A1 (en) * | 2002-09-18 | 2004-03-18 | Thomas Ryll | Method for production of a multimeric protein by cell fusion |
JP4033390B2 (ja) * | 2002-10-30 | 2008-01-16 | 独立行政法人科学技術振興機構 | 不死化ナチュラルキラー細胞株 |
WO2004055056A1 (en) | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
US7883703B2 (en) | 2003-11-14 | 2011-02-08 | The Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
RU2370276C2 (ru) | 2003-12-31 | 2009-10-20 | Мерк Патент Гмбх | Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ |
ES2330860T3 (es) | 2004-01-22 | 2009-12-16 | Merck Patent Gmbh | Anticuerpos anticancerosos con fijacion del complemento reducida. |
JP2008528060A (ja) | 2005-01-27 | 2008-07-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ボツリヌス神経毒素を中和する治療的モノクローナル抗体 |
EP2682126B1 (en) | 2005-01-27 | 2016-11-23 | Children's Hospital & Research Center at Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
KR101397290B1 (ko) * | 2005-12-30 | 2014-05-21 | 메르크 파텐트 게엠베하 | 감소한 면역원성을 가지는 항-cd19 항체 |
EP2348052A3 (en) | 2007-09-17 | 2011-10-26 | The Regents of The University of California | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
JP5809415B2 (ja) | 2007-11-09 | 2015-11-10 | ペレグリン ファーマシューティカルズ,インコーポレーテッド | 抗vegf抗体の組成物および方法 |
US10035834B2 (en) | 2008-06-18 | 2018-07-31 | The Texas A&M University System | Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage |
EP2680004B1 (en) | 2010-01-15 | 2016-08-31 | The Regents of The University of California | Methods for detecting cancer |
EP2525822B1 (en) | 2010-01-20 | 2017-05-10 | Merck Sharp & Dohme Corp. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
EP2525813B1 (en) | 2010-01-20 | 2017-01-04 | Merck Sharp & Dohme Corp. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
JP5837567B2 (ja) | 2010-03-26 | 2015-12-24 | メモリアル スローン−ケタリング キャンサー センター | Muc16に対する抗体およびその使用方法 |
SI2556090T1 (sl) | 2010-04-09 | 2016-07-29 | Critical Care Diagnostics, Inc. | Protitelesa in testi topnega človeškega ST-2 |
CA2804976A1 (en) | 2010-04-29 | 2011-11-03 | Hadasit Medical Research Services And Development Ltd. | Methods and compositions for treating hepatitis with anti-cd3 immune molecule therapy |
WO2012027440A1 (en) | 2010-08-24 | 2012-03-01 | Abbott Laboratories | Hiv core protein specific antibodies and uses thereof |
WO2012075173A2 (en) | 2010-12-01 | 2012-06-07 | Board Of Regents The University Of Texas System | Compositions and method for deimmunization of proteins |
WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
EP2836514A4 (en) | 2012-04-13 | 2015-12-30 | Childrens Medical Center | TIKI INHIBITORS |
EP2931293B1 (en) | 2012-12-12 | 2019-02-20 | University Of Virginia Patent Foundation | Compositions and methods for regulating erythropoiesis |
EP2968550B1 (en) | 2013-03-14 | 2018-11-14 | Ffe Therapeutics LLC | Compositions and methods for treating angiogenesis-related disorders |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
FI3218005T3 (fi) | 2014-11-12 | 2023-03-31 | Seagen Inc | Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä |
IL296062A (en) | 2015-03-17 | 2022-10-01 | Memorial Sloan Kettering Cancer Center | Antibodies against muc16 and their uses |
AU2016282986A1 (en) | 2015-06-26 | 2018-02-01 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
EP3373969A4 (en) | 2015-11-12 | 2019-08-14 | Siamab Therapeutics, Inc. | GLYCANINTERAGING COMPOUNDS AND METHOD OF USE |
EP3383920B1 (en) | 2015-11-30 | 2024-01-10 | The Regents of the University of California | Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen |
US11401330B2 (en) | 2016-11-17 | 2022-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
JP2020510671A (ja) | 2017-03-03 | 2020-04-09 | シアトル ジェネティックス, インコーポレイテッド | グリカン相互作用化合物および使用の方法 |
CN108727494A (zh) * | 2017-04-25 | 2018-11-02 | 成都贝爱特生物科技有限公司 | 一种靶向筛选外源基因双整合位点提高人c5单抗表达产量的方法 |
US11464845B2 (en) | 2017-07-21 | 2022-10-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neisseria meningitidis immunogenic compositions |
MA50102A (fr) | 2017-11-14 | 2020-07-15 | Univ Virginia Patent Foundation | Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
KR20210016390A (ko) | 2018-06-01 | 2021-02-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
SG11202111281TA (en) | 2019-05-21 | 2021-12-30 | Novartis Ag | Cd19 binding molecules and uses thereof |
US20230071196A1 (en) | 2019-05-21 | 2023-03-09 | Novartis Ag | Variant cd58 domains and uses thereof |
US20230340086A1 (en) | 2019-06-19 | 2023-10-26 | Christopher Roland Oelkrug | Antibody-mediated neutralization of beta-lactamases |
TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與entpd2抗體之組合療法 |
WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
WO2021097338A1 (en) | 2019-11-15 | 2021-05-20 | Pliant Therapeutics, Inc. | Compositions and methods for activation of integrins |
IL296276A (en) | 2020-03-10 | 2022-11-01 | Tiziana Life Sciences Plc | Antibody preparations for il-6/il-6r and methods of using them |
CA3175784A1 (en) | 2020-06-17 | 2021-12-23 | Kunwar Shailubhai | Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies |
AU2021316723A1 (en) | 2020-07-30 | 2023-01-19 | Tiziana Life Sciences Plc | CD-3 antibodies for the treatment of coronavirus |
CA3188728A1 (en) | 2020-08-07 | 2022-02-10 | Marc Nasoff | Immunoconjugates targeting cd46 and methods of use thereof |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
CA3199839A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
EP4284510A1 (en) | 2021-01-29 | 2023-12-06 | Novartis AG | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
WO2022221409A1 (en) | 2021-04-14 | 2022-10-20 | Villaris Therapeutics, Inc. | Anti-cd122 antibodies and uses thereof |
US20220332822A1 (en) | 2021-04-16 | 2022-10-20 | Tiziana Life Sciences Plc | Subcutaneous administration of antibodies for the treatment of disease |
CA3234994A1 (en) | 2021-10-14 | 2023-04-20 | Tiziana Life Sciences Plc | Methods of suppressing microglial activation |
AU2022386323A1 (en) | 2021-11-09 | 2024-05-16 | Sensei Biotherapeutics, Inc. | Anti-vista antibodies and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0173494A3 (en) * | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) * | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
EP0245949B1 (en) * | 1986-04-09 | 1997-10-29 | Eli Lilly And Company | A method of using eukaryotic expression vectors comprising the bk virus enhancer |
EP0256654B1 (en) * | 1986-07-07 | 1996-09-18 | Centocor, Inc. | Chimeric murine/human immunoglobulin specific for tumour-associated 17-1A Antigen |
-
1988
- 1988-04-21 US US07/184,522 patent/US4975369A/en not_active Expired - Fee Related
-
1989
- 1989-04-18 PH PH38523A patent/PH26945A/en unknown
- 1989-04-18 EP EP19890303814 patent/EP0338767A3/en not_active Withdrawn
- 1989-04-18 ZA ZA892840A patent/ZA892840B/xx unknown
- 1989-04-18 IL IL90016A patent/IL90016A0/xx unknown
- 1989-04-19 NZ NZ228801A patent/NZ228801A/en unknown
- 1989-04-19 DK DK187889A patent/DK187889A/da not_active Application Discontinuation
- 1989-04-19 AU AU33189/89A patent/AU621600B2/en not_active Expired - Fee Related
- 1989-04-19 PT PT90312A patent/PT90312A/pt not_active Application Discontinuation
- 1989-04-20 JP JP1103278A patent/JPH02211877A/ja active Pending
- 1989-04-20 CN CN89102396A patent/CN1037174A/zh active Pending
- 1989-04-20 HU HU891925A patent/HUT50870A/hu unknown
- 1989-04-20 KR KR1019890005191A patent/KR900016459A/ko not_active Application Discontinuation
-
1990
- 1990-04-25 RU SU904743669A patent/RU1780541C/ru active
Also Published As
Publication number | Publication date |
---|---|
EP0338767A2 (en) | 1989-10-25 |
DK187889D0 (da) | 1989-04-19 |
ZA892840B (en) | 1990-12-28 |
NZ228801A (en) | 1991-05-28 |
DK187889A (da) | 1989-10-23 |
RU1780541C (ru) | 1992-12-07 |
EP0338767A3 (en) | 1991-07-17 |
HUT50870A (en) | 1990-03-28 |
CN1037174A (zh) | 1989-11-15 |
AU3318989A (en) | 1989-10-26 |
AU621600B2 (en) | 1992-03-19 |
IL90016A0 (en) | 1989-12-15 |
US4975369A (en) | 1990-12-04 |
JPH02211877A (ja) | 1990-08-23 |
PT90312A (pt) | 1989-11-10 |
PH26945A (en) | 1992-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR900016459A (ko) | 사람의 선암(adenocarcinoma)항원에 대한 재조합 및 키메릭 항체 | |
Molday et al. | The cGMP-gated channel of the rod photoreceptor cell characterization and orientation of the amino terminus. | |
TIMPL et al. | Nature of the collagenous protein in a tumor basement membrane | |
Falkner et al. | Two Drosophila melanogaster proteins related to intermediate filament proteins of vertebrate cells. | |
Goding | Conjugation of antibodies with fluorochromes: modifications to the standard methods | |
Solomon | Bence Jones Proteins and Light Chains of Immunoglobulins. | |
Poljak | Three-dimensional structure, function and genetic control of immunoglobulins | |
Schröder et al. | Purification of brain tubulin-tyrosine ligase by biochemical and immunological methods. | |
Cone et al. | Isolation of membrane associated immunoglobulins from T lymphocytes by non-ionic detergents | |
KR970707160A (ko) | 인체 인터루킨 5 수용체 알파-사슬에 대한 항체 (antibody against alpha-chain of human interleukin 5 receptor) | |
AU633336B2 (en) | Chimeric antibodies directed against a human glycoprotein antigen | |
KR950700419A (ko) | 단량체 및 이량체 항체-단편 융합 단백질(monomeric and dimeric antibody-fragment fusion proteins) | |
CA2296272A1 (en) | Mammalian cytokine: interleukin-b30 and related reagents | |
Knopf et al. | Biosynthetic units of an immunoglobulin heavy chain. | |
Schulenburg et al. | Amino acid sequence of the light chain from a mouse myeloma protein with anti-hapten activity: evidence for a third type of light chain | |
Weir et al. | Comparison of the structure of the immunoglobulins from horse serum | |
FI941048A0 (fi) | Geloniinipolypeptidin koodaavia DNA-sekvenssejä | |
Nalefski et al. | Nature of the ligand recognized by a hapten-and carrier-specific, MHC-restricted T cell receptor. | |
Francus et al. | An IgG2a-producing variant of an IgG2b-producing mouse myeloma cell line. Structural studies on the Fc region of parent and variant heavy chains | |
Lopes et al. | Lymphocyte plasma membranes: analysis of proteins and glycoproteins by SDS-gel electrophoresis | |
Sledge et al. | Antibody structure: amino terminal sequences of nurse shark light and heavy chains | |
Firca et al. | Interconversion of conformational isomers of light chains in the Mcg immunoglobulins | |
KR870004137A (ko) | 항인간 인터로이킨 1항체(Anti Hunam Interleukin 1 Antibody)와 그의 제법 및 그의 사용법 | |
JPS6470498A (en) | Synthetic peptide and antibody thereto | |
Wang et al. | Cleavage sites of human IgGl immunoglobulin by papain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |